NoAb BioDiscoveries this week launched DTEx, a microarray-based technology that profiles the effects of drugs on the gene expression of key proteins involved in drug metabolism.
DTEx analyzes the effects of drugs on the induction or suppression of transporter genes that play a critical role in determining the pharmacodynamic and pharmacokinetic properties of administered drugs. “This information will help scientists understand potential drug-drug interactions and to select candidates for clinical development with greater efficacy and fewer side effects,” NoAb said. The company has filed patent applications for the DTEx technology.